Attachment
Gates Package, p.262 [Q2 2021] · gates:exh:00155
Page text: p.262 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
- Topics
- Therapeutics and treatments
Merck
Remdesivir
and Antiviral/Immune__
Injection
Repurposed
Q1 2021
IFN-beta (Rebif)
Modulator
Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC)
Gilead & Other
Remdesivir and
Antiviral
Intravenous
N/A
Q3 2021
Hyperimmune
Intravenous
Immunoglobulin
(hIVIG)
Convalescent Plasma in Outpatients with COVID-19 (C3PO)
Other
Convalescent
Convalescent
Intravenous
N/A
Q4 2022
Plasma
Plasma
Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients (CONTAIN
COVID-19)
Other
Convalescent
Convalescent
Intravenous
N/A
Q2 2021
Plasma
Plasma
Passive Immunity Trial of Our Nation (PassItOn) Inpatient
Other
Convalescent
Convalescent
Intravenous
N/A
Plasma
Plasma
This page last reviewed on February 12, 2021
3/3